Gyre Therapeutics Posts Q2 2026 Revenue of $29.1M, Reaffirms Full-Year Outlook, and Spotlights F351 NDA Acceptance
GYRE sits 18% above its 52-week low of $5.44.
Summary
Gyre Therapeutics delivered Q2 2026 revenue of $29.1M and a GAAP loss of $0.12 per share, reaffirmed its full-year revenue guidance, and detailed progress across its fibrosis and targeted protein degradation pipelines following the Cullgen acquisition.
Key Events · Earnings and Guidance · GYRE
-
Q2 Revenue and EPS
Revenue came in at $29.1M, a 2% decline year-over-year, while GAAP basic EPS swung to $(0.12) from $(0.02) in Q2 2025.
-
Full-Year Guidance Affirmed
Management reaffirmed its 2026 revenue guidance of $100.5M to $111.0M.
-
Cash Position
Cash, equivalents, and investments totaled $103.2M at quarter-end, down from $116.1M at year-end 2025.
-
R&D Expense Surge
R&D expense jumped 129% to $19.1M, fueled by a $4.8M milestone payment tied to the F351 NDA acceptance and higher clinical trial costs.
Analysis · GYRE · Life Sciences
The quarter's results underscore a sharp ramp in R&D spending and a net loss of $14.3M, yet management stood by its full-year revenue target of $100.5–$111.0M and closed the period with $103.2M in cash. Two milestones carry the narrative: the NDA acceptance for F351 in liver fibrosis and the completion of the Cullgen acquisition. While the pipeline is advancing, the burn rate is accelerating. With the stock well off its 52-week high, investors will balance near-term dilution from the Cullgen deal against the long-term promise of the pipeline.
At the time of this filing, GYRE was trading at $6.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $713.5M. The 52-week trading range was $5.44 to $9.42. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.